Famvir Tablet (Famciclovir)

Adult dose

1. Treatment of herpes zoster Adults: Administer famciclovir 250 mg orally 3 times daily for 7 days. It is preferable to start treatment as soon as symptoms appear after infection. 2. Treatment of an initial episode of genital herpes Adults: Administer this medicine 250 mg orally 3 times daily for 5 days. It is preferable to start treatment as soon as symptoms appear after infection. 3. Treatment of acute recurrent genital herpes Adults: Administer this medicine 125 mg orally 2 times daily for 5 days. It is preferable to start treatment during the prodromal period or as soon as symptoms appear after infection. 4. Suppression of recurrent genital herpes Adults: Administer this medicine 250 mg orally 2 times daily. Interrupt treatment periodically every 6～12 months to observe whether the natural course of the disease has changed. 5. Patients with renal impairment: Since the clearance of this medicine is reduced in patients with renal impairment, dose adjustment should be undertaken with caution. The dosage for these patients is as follows. 1) Treatment of herpes zoster and an initial episode of genital herpes: Creatinine clearance (mL/min/1.73㎡) Dose 30～59 250 mg per dose, 2 times daily 10～29 250 mg per dose, once daily 2) Treatment of acute recurrent genital herpes: Creatinine clearance (mL/min/1.73㎡) Dose 30～59 125 mg per dose, 2 times daily 10～29 125 mg per dose, once daily 3) Suppression of recurrent genital herpes: Creatinine clearance (mL/min/1.73㎡) Dose 30～59 250 mg per dose, 2 times daily 10～29 125 mg per dose, 2 times daily 4) If only the serum creatinine level is known, creatinine clearance can be calculated using the following equations. Men: {body weight(kg) × (140-age)}/ {72 × serum creatinine(mg/dL)} Women: 0.85 × the value calculated for men 5) Patients with renal impairment undergoing hemodialysis For patients on hemodialysis, administration every 48 hours, taking the dialysis interval into account, is preferable. A 4-hour hemodialysis session reduces the plasma concentration of this medicine by approximately 75%; therefore, administer this medicine immediately after dialysis. The recommended dose is 250mg for patients with herpes zoster and 125mg for patients with genital herpes. 6. Patients with hepatic impairment: No dose adjustment is required in patients with chronic compensated liver disease. There is insufficient treatment experience in patients with overt chronic decompensated liver disease; therefore, no clear recommended dose has been established.

This medication should not be administered to certain patients. First, it should not be used in patients who have had allergic reactions to this medication or its ingredient, penciclovir. Additionally, this medication contains lactose, so patients with lactose intolerance or specific genetic metabolic disorders should not take it. Patients with allergies to soybean oil, soy, peanuts, etc., should also avoid this medication. Caution should be taken when administering this medication to patients with poor kidney function or lipid metabolism issues, especially in those with hyperlipidemia, diabetic dyslipidemia, and pancreatitis. During treatment with this medication, symptoms such as headache, dizziness, nausea, vomiting, abdominal pain, and diarrhea may commonly occur. Rarely, serious adverse reactions such as decreased blood cell count, hallucinations, palpitations, skin rashes or itching, and acute renal failure may also occur, so symptoms should be monitored closely. This medication cannot cure genital herpes; during treatment, it is recommended to avoid sexual contact and maintain safe sexual practices if symptoms are present. If dizziness, drowsiness, or confusion occur during medication, driving or operating machinery should be avoided. Patients with slightly impaired liver function do not require special dose adjustments, but those with severe liver disease may experience decreased efficacy. Patients with fatty overload should monitor blood lipid levels and adjust the medication dosage if necessary. This medication has a low likelihood of interactions with other drugs, but caution is required when combined with certain medications such as probenecid, as it may increase blood concentration. When used in conjunction with tamoxifen, therapy effects should be closely monitored. Women who are pregnant or may become pregnant should have the use of this medication carefully considered, and breastfeeding women should weigh the risks and benefits before taking it. Children under 18 years of age should avoid this medication as safety and efficacy have not been established. Generally, elderly patients do not require dose adjustments; however, those with diminished kidney function may need adjustments. In the case of an overdose, appropriate treatment alongside hemodialysis may be beneficial. This medication should be stored in a tightly closed container to protect against air and moisture, and it is important to store it in a cool, dry place at a temperature below 30 degrees Celsius, keeping it out of reach of children and avoiding transfer to another container.

• Headache
• nausea
• thrombocytopenia
• leukopenia
• neutropenia
• dizziness
• confusion
• drowsiness
• hallucinations
• palpitations

This medication should be stored in a tightly sealed container to protect it from air and moisture, and it is important to store it in a cool, dry place at a temperature below 30 degrees Celsius.

Appearance

White round film-coated tablet

Package unit

21 tablets (7T/PTPX3)/case